Compare LQDT & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDT | MGTX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 909.1M |
| IPO Year | 2005 | 2018 |
| Metric | LQDT | MGTX |
|---|---|---|
| Price | $34.50 | $9.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $40.00 | $24.57 |
| AVG Volume (30 Days) | 140.0K | ★ 646.7K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.10 | 33.02 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $476,669,000.00 | $81,391,000.00 |
| Revenue This Year | N/A | $141.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $74.30 | ★ N/A |
| Revenue Growth | 31.20 | ★ 144.57 |
| 52 Week Low | $21.67 | $5.02 |
| 52 Week High | $38.83 | $11.85 |
| Indicator | LQDT | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 46.35 |
| Support Level | $30.51 | $8.75 |
| Resistance Level | $38.83 | $9.65 |
| Average True Range (ATR) | 1.28 | 0.43 |
| MACD | -0.21 | -0.09 |
| Stochastic Oscillator | 26.66 | 21.87 |
Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Retail Supply Chain Group (RSCG), and Machinio & Software Solutions. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.